Vital Therapies Considers New Trial Of ELAD Liver Therapy After Trial Misses Endpoint
This article was originally published in Clinica
Executive Summary
Vital Therapies, Inc. is assessing its options for moving forward with its stem cell-based bio-artificial liver therapy, ELAD, after the VTI-208 pivotal trial failed to meet its primary endpoint.